{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:05:53Z","timestamp":1757617553309,"version":"3.44.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ministry of Science and Culture of Lower Saxony, Germany"},{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Interleukin-6 (IL-6) is a multifunctional cytokine with important functions in health and disease. In order to activate its target cells, IL-6 binds first to the IL-6 receptor (IL-6R), which in turn induces the recruitment and homodimerization of the signal-transducing \u03b2-receptor gp130 and the activation of intracellular signaling cascades, including the phosphoinositide 3-kinase (PI3K)-AKT cascade. IL-6 is involved in the pathogenesis of multiple inflammatory diseases, and tocilizumab, a monoclonal antibody that binds to the IL-6R and thus blocks the biological activities of IL-6, is in clinical use worldwide for the treatment of patients with inflammatory diseases, including rheumatoid arthritis. Recently, Weng and colleagues published a paper in <jats:italic>Naunyn\u2013Schmiedeberg\u2019s Archives of Pharmacology<\/jats:italic> describing paradoxical effects of tocilizumab when used on murine cells in vitro and in a rat model of acute lung injury in vivo. In this communication, I provide evidence that the results presented by Weng and colleagues are not compatible with what is known about the biology of IL-6 and highlight why the provided evidence is insufficient to believe that tocilizumab shows the reported paradoxical effects in rodents.<\/jats:p>","DOI":"10.1007\/s00210-025-04021-1","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T07:52:07Z","timestamp":1741765927000},"page":"11061-11064","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["No evidence for paradoxical effects of tocilizumab in rodents"],"prefix":"10.1007","volume":"398","author":[{"given":"Christoph","family":"Garbers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"4021_CR1","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1002\/eji.1830191121","volume":"19","author":"PG Coulie","year":"1989","unstructured":"Coulie PG, Stevens M, Van Snick J (1989) High- and low-affinity receptors for murine interleukin 6. Distinct distribution on B and T cells. Eur J Immunol 19:2107\u20132114","journal-title":"Eur J Immunol"},{"key":"4021_CR2","unstructured":"EMA Assessment Report for tocilizumab (n.d.) https:\/\/www.emaeuropaeu\/en\/documents\/variation-report\/roactemra-h-c-955-ii-0015-epar-assessment-report-variation_enpdf. Accessed 2 Feb 2025"},{"key":"4021_CR3","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.ejcb.2011.09.010","volume":"91","author":"R Eulenfeld","year":"2012","unstructured":"Eulenfeld R, Dittrich A, Khouri C, Muller PJ, Mutze B, Wolf A, Schaper F (2012) Interleukin-6 signalling: more than Jaks and STATs. Eur J Cell Biol 91:486\u2013495","journal-title":"Eur J Cell Biol"},{"key":"4021_CR4","doi-asserted-by":"publisher","first-page":"100434","DOI":"10.1016\/j.jbc.2021.100434","volume":"296","author":"CM Flynn","year":"2021","unstructured":"Flynn CM, Kespohl B, Daunke T, Garbers Y, D\u00fcsterh\u00f6ft S, Rose-John S, Haybaeck J, Lokau J, Aparicio-Siegmund S, Garbers C (2021) Interleukin-6 controls recycling and degradation, but not internalization of its receptors. J Biol Chem 296:100434","journal-title":"J Biol Chem"},{"key":"4021_CR5","doi-asserted-by":"publisher","first-page":"42959","DOI":"10.1074\/jbc.M111.295758","volume":"286","author":"C Garbers","year":"2011","unstructured":"Garbers C, Thaiss W, Jones GW, Waetzig GH, Lorenzen I, Guilhot F, Lissilaa R, Ferlin WG, Gr\u00f6tzinger J, Jones SA, Rose-John S, Scheller J (2011) Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem 286:42959\u201342970","journal-title":"J Biol Chem"},{"key":"4021_CR6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nrd.2018.45","volume":"17","author":"C Garbers","year":"2018","unstructured":"Garbers C, Heink S, Korn T, Rose-John S (2018) Interleukin-6: designing specific therapeutics for a complex cytokine. Nat Rev Drug Discov 17:395\u2013412","journal-title":"Nat Rev Drug Discov"},{"key":"4021_CR7","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jacbts.2021.01.013","volume":"6","author":"MJ George","year":"2021","unstructured":"George MJ, Jasmin NH, Cummings VT, Richard-Loendt A, Launchbury F, Woollard K, Turner-Stokes T, Garcia Diaz AI, Lythgoe M, Stuckey DJ, Hingorani AD, Gilroy DW (2021) Selective interleukin-6 trans-signaling blockade is more effective than panantagonism in reperfused myocardial infarction. JACC Basic Transl Sci 6:431\u2013443","journal-title":"JACC Basic Transl Sci"},{"key":"4021_CR8","doi-asserted-by":"publisher","first-page":"e0232612","DOI":"10.1371\/journal.pone.0232612","volume":"15","author":"J Lokau","year":"2020","unstructured":"Lokau J, Kleinegger F, Garbers Y, Waetzig GH, Gr\u00f6tzinger J, Rose-John S, Haybaeck J, Garbers C (2020) Tocilizumab does not block interleukin-6 (IL-6) signaling in murine cells. PLoS ONE 15:e0232612","journal-title":"PLoS ONE"},{"key":"4021_CR9","doi-asserted-by":"publisher","first-page":"22822","DOI":"10.18632\/oncotarget.4477","volume":"6","author":"D Mochizuki","year":"2015","unstructured":"Mochizuki D, Adams A, Warner KA, Zhang Z, Pearson AT, Misawa K, McLean SA, Wolf GT, Nor JE (2015) Anti-tumor effect of inhibition of IL-6 signaling in mucoepidermoid carcinoma. Oncotarget 6:22822\u201322835","journal-title":"Oncotarget"},{"key":"4021_CR10","doi-asserted-by":"publisher","first-page":"4713","DOI":"10.4049\/jimmunol.166.7.4713","volume":"166","author":"MM Monick","year":"2001","unstructured":"Monick MM, Carter AB, Robeff PK, Flaherty DM, Peterson MW, Hunninghake GW (2001) Lipopolysaccharide activates Akt in human alveolar macrophages resulting in nuclear accumulation and transcriptional activity of beta-catenin. J Immunol 166:4713\u20134720","journal-title":"J Immunol"},{"issue":"Suppl 1","key":"4021_CR11","doi-asserted-by":"publisher","first-page":"i21","DOI":"10.1136\/ard.59.suppl_1.i21","volume":"59","author":"N Nishimoto","year":"2000","unstructured":"Nishimoto N, Kishimoto T, Yoshizaki K (2000) Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis 59(Suppl 1):i21-27","journal-title":"Ann Rheum Dis"},{"key":"4021_CR12","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","volume":"112","author":"N Nishimoto","year":"2008","unstructured":"Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T (2008) Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112:3959\u20133964","journal-title":"Blood"},{"key":"4021_CR13","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S0165-2478(02)00202-X","volume":"84","author":"M Okazaki","year":"2002","unstructured":"Okazaki M, Yamada Y, Nishimoto N, Yoshizaki K, Mihara M (2002) Characterization of anti-mouse interleukin-6 receptor antibody. Immunol Lett 84:231\u2013240","journal-title":"Immunol Lett"},{"key":"4021_CR14","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/j.bbagen.2012.08.014","volume":"1820","author":"A Patruno","year":"2012","unstructured":"Patruno A, Franceschelli S, Pesce M, Maccallini C, Fantacuzzi M, Speranza L, Ferrone A, De Lutiis MA, Ricciotti E, Amoroso R, Felaco M (2012) Novel aminobenzyl-acetamidine derivative modulate the differential regulation of NOSs in LPS induced inflammatory response: role of PI3K\/Akt pathway. Biochim Biophys Acta 1820:2095\u20132104","journal-title":"Biochim Biophys Acta"},{"key":"4021_CR15","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.3899\/jrheum.121389","volume":"40","author":"K Shimamoto","year":"2013","unstructured":"Shimamoto K, Ito T, Ozaki Y, Amuro H, Tanaka A, Nishizawa T, Son Y, Inaba M, Nomura S (2013) Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis. J Rheumatol 40:1074\u20131081","journal-title":"J Rheumatol"},{"key":"4021_CR16","doi-asserted-by":"publisher","first-page":"7851","DOI":"10.3168\/jds.2020-18187","volume":"103","author":"L Sun","year":"2020","unstructured":"Sun L, Tian W, Guo X, Zhang Y, Liu X, Li X, Tian Y, Man C, Jiang Y (2020) Lactobacillus gasseri JM1 with potential probiotic characteristics alleviates inflammatory response by activating the PI3K\/Akt signaling pathway in vitro. J Dairy Sci 103:7851\u20137864","journal-title":"J Dairy Sci"},{"key":"4021_CR17","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1186\/s12964-024-01775-8","volume":"22","author":"Y Tabei","year":"2024","unstructured":"Tabei Y, Nakajima Y (2024) IL-1beta-activated PI3K\/AKT and MEK\/ERK pathways coordinately promote induction of partial epithelial-mesenchymal transition. Cell Commun Signal 22:392","journal-title":"Cell Commun Signal"},{"key":"4021_CR18","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/srep01196","volume":"3","author":"O Ueda","year":"2013","unstructured":"Ueda O, Tateishi H, Higuchi Y, Fujii E, Kato A, Kawase Y, Wada NA, Tachibe T, Kakefuda M, Goto C, Kawaharada M, Shimaoka S, Hattori K, Jishage K (2013) Novel genetically-humanized mouse model established to evaluate efficacy of therapeutic agents to human interleukin-6 receptor. Sci Rep 3:1196","journal-title":"Sci Rep"},{"key":"4021_CR19","doi-asserted-by":"publisher","first-page":"15285","DOI":"10.1016\/S0021-9258(18)82467-X","volume":"268","author":"M van Dam","year":"1993","unstructured":"van Dam M, M\u00fcllberg J, Schooltink H, Stoyan T, Brakenhoff JP, Graeve L, Heinrich PC, Rose-John S (1993) Structure-function analysis of interleukin-6 utilizing human\/murine chimeric molecules. Involvement of two separate domains in receptor binding. J Biol Chem 268:15285\u201315290","journal-title":"J Biol Chem"},{"key":"4021_CR20","doi-asserted-by":"publisher","unstructured":"Weng J, Weng S, Xu J, Liu D, Guo R, Shi B, Chen M (2025) Tocilizumab alleviated lipopolysaccharide-induced acute lung injury by improving PI3K\/AKT pathway. Naunyn Schmiedebergs Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-025-03786-9","DOI":"10.1007\/s00210-025-03786-9"},{"key":"4021_CR21","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.chembiol.2009.06.010","volume":"16","author":"M Wiesinger","year":"2009","unstructured":"Wiesinger M, Haan S, W\u00fcller S, Kauffmann M-E, Recker T, K\u00fcster A, Heinrich P, M\u00fcller-Newen G (2009) Development of an IL-6 inhibitor based on the functional analysis of murine IL-6Ralpha(1). Chem Biol 16:783\u2013794","journal-title":"Chem Biol"},{"key":"4021_CR22","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1186\/s13287-022-03178-3","volume":"13","author":"C Xu","year":"2022","unstructured":"Xu C, Feng C, Huang P, Li Y, Liu R, Liu C, Han Y, Chen L, Ding Y, Shao C, Shi Y (2022) TNFalpha and IFNgamma rapidly activate PI3K-AKT signaling to drive glycolysis that confers mesenchymal stem cells enhanced anti-inflammatory property. Stem Cell Res Ther 13:491","journal-title":"Stem Cell Res Ther"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04021-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04021-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04021-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T09:06:40Z","timestamp":1757149600000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04021-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["4021"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04021-1","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"type":"print","value":"0028-1298"},{"type":"electronic","value":"1432-1912"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"assertion":[{"value":"28 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}